What is Placebo Comparator: N/S 0.9% used for?

Placebo Comparator: N/S 0.9% is indicated for Clinical trial control/comparator agent.

Who makes Placebo Comparator: N/S 0.9%?

Placebo Comparator: N/S 0.9% is developed by Aristotle University Of Thessaloniki.

What development phase is Placebo Comparator: N/S 0.9% in?

Placebo Comparator: N/S 0.9% is FDA-approved (marketed).

What are the side effects of Placebo Comparator: N/S 0.9%?

Common side effects include Injection site reactions, Fluid overload (with high-volume administration).

Last reviewed 2026-04-22 · How we verify

Placebo Comparator: N/S 0.9%

Aristotle University Of Thessaloniki · FDA-approved active Small molecule

Normal saline (0.9% sodium chloride) is an inert isotonic solution used as a control comparator in clinical trials.

Normal saline (0.9% sodium chloride) is an inert isotonic solution used as a control comparator in clinical trials. Used for Clinical trial control/comparator agent.

At a glance

Generic name	Placebo Comparator: N/S 0.9%
Sponsor	Aristotle University Of Thessaloniki
Modality	Small molecule
Phase	FDA-approved

Mechanism of action

Normal saline serves as a physiologically neutral vehicle that maintains osmotic balance with body fluids. It is commonly used as a placebo or control arm in clinical trials to establish baseline efficacy and safety profiles of investigational drugs. As a comparator, it provides no active therapeutic mechanism.

Approved indications

Clinical trial control/comparator agent

Common side effects

Injection site reactions
Fluid overload (with high-volume administration)

Key clinical trials

Safety Evaluation of PfSPZ Vaccine in Pregnant Women in Mali (MalVIP1) (PHASE1)
HB-adMSCs for the Treatment of Crohn's Disease (PHASE2)
Role of Airway Topicalization in Awake Fiberoptic Intubation (PHASE3)
Phase 2 Shigella Vaccine and Challenge (PHASE2)
Personalized Immunotherapy in Sepsis (PHASE2)
Use of Presepsin as a Marker for Immunotherapy Administration in Pneumonia (PHASE2)
Ropivacaine Plus Magnesium Sulphate Infiltration (PHASE4)
A 2nd Generation E1/E2B/E3-Deleted Adenoviral COVID-19 Vaccine: The TCELL VACCINE TRIAL (PHASE2, PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Placebo Comparator: N/S 0.9% CI brief — competitive landscape report
Placebo Comparator: N/S 0.9% updates RSS · CI watch RSS
Aristotle University Of Thessaloniki portfolio CI